RemeGen Deal History & Licensing Activity
RemeGen is a biotech headquartered in China. Over the past three years, RemeGen has been involved in 9 licensing and acquisition transactions, with a primary focus on RNAi (3 deals). The company currently has 41 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
41
Top Modality
RNAi
Focus Area
Solid Tumors
RemeGen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving RemeGen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Anti-BRAF V600E-101 | Bristol-Myers Squibb | mRNA | Phase 3 | co development | Sep 2025 |
| WEE1 | Roche | CAR-T | Phase 2 | acquisition | Aug 2025 |
| Anti-WEE1-tinib | Pfizer | RNAi | Preclinical | collaboration | Jul 2025 |
RemeGen Pipeline Focus
Therapeutic areas and modalities where RemeGen is most active based on deal history and clinical trial data.
Therapeutic Areas
RemeGen Strategic Signals
Key indicators of RemeGen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
RemeGen Clinical Pipeline
RemeGen has 41 active clinical trials across 4 development phases.
1
Not Applicable
11
Phase 1
21
Phase 2
8
Phase 3
See How Your Asset Matches RemeGen's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
RNAi Benchmarks
Upfront, milestone, and royalty benchmarks for rnai deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About RemeGen Licensing & Deal Activity
RemeGen is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 9 deals over the past three years, RemeGen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for RemeGen include Solid Tumors (26 deals and trials), Oncology (9 deals and trials), Immunology (4 deals and trials), and CNS Disorders (2 deals and trials). In terms of modality, RemeGen has shown particular interest in rnai, other, mrna.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for RemeGen and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against RemeGen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.